Scientific publications

Cystic pancreatic neuroendocrine tumors (cPNETs): a systematic review and meta-analysis of case series

Nov 1, 2017 | Magazine: Revista Española de Enfermedades Digestivas

Luis Hurtado-Pardo  1 , Javier A Cienfuegos  2 , Miguel Ruiz-Canela  3 , Pablo Panadero  4 , Alberto Benito  5 , José Luis Hernández Lizoain  6


Cystic pancreatic neuroendocrine tumors represent 13% of all neuroendocrine tumors.

The aim of this study is to analyze the phenotype and biologic behavior of resected cystic neuroendocrine tumors. A systematic review and meta-analysis were conducted until September 2016 using a search in Medline, Scopus, and EMBASE with the terms "cystic pancreatic endocrine neoplasm", "cystic islets tumors" and "cystic islets neoplasms".

From the 795 citations recovered 80 studies reporting on 431 patients were selected. 87.1% (n = 387) were sporadic tumors and 10.3% (n = 40) corresponded to multiple endocrine neoplasia endocrine type 1. Were diagnosed incidentally 44.6% (n = 135). Cytology was found to have a sensitivity of 78.5%. Were non-functional tumors 85% (n = 338), and among the functional tumors, insulinoma was the most frequent.

According to the European Neuroendocrine Tumor Society staging, 87.8% were limited to the pancreas (I-IIb), and 12.2% were advanced (III-IV). Disease-free survival at 5 years in stages (I-IIIa) and (IIIb-IV) was 91.5% and 54.2%, respectively; and was significantly lower (p = 0.0001) in functional tumors. In patients with multiple endocrine neoplasia there was a higher incidence of functional (62.5%) and multifocal (28.1%) tumors. Disease-free survival at 5 and 10 years was 60%.

Cystic pancreatic neuroendocrine tumors exhibit phenotypical characteristics which are different to those of solid neuroendocrine tumors.

CITATION Rev Esp Enferm Dig. 2017 Nov;109(11):778-787.  doi: 10.17235/reed.2017.5044/2017

Our authors